Healthcare & Life Sciences
GLYCART biotechnology AG
Switzerland
acquiredacquired
acquired
Stage
About
GLYCART biotechnology AG was a Swiss biotechnology company that developed engineered glyco-engineered antibody-based therapeutics targeting unmet clinical needs such as cancer. The company was acquired by Roche in 2005 for CHF 230 million.
Explore GLYCART biotechnology AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.